CN108697746A - 编码抗tcr复合体抗体或片段的病毒 - Google Patents

编码抗tcr复合体抗体或片段的病毒 Download PDF

Info

Publication number
CN108697746A
CN108697746A CN201680076032.7A CN201680076032A CN108697746A CN 108697746 A CN108697746 A CN 108697746A CN 201680076032 A CN201680076032 A CN 201680076032A CN 108697746 A CN108697746 A CN 108697746A
Authority
CN
China
Prior art keywords
virus
oncolytic virus
cells
antibody
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680076032.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·C·N·布朗利
B·R·查普恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akamis Bio Ltd
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1522334.0A external-priority patent/GB201522334D0/en
Priority claimed from GBGB1607463.5A external-priority patent/GB201607463D0/en
Priority claimed from GBGB1617206.6A external-priority patent/GB201617206D0/en
Priority claimed from GBGB1617207.4A external-priority patent/GB201617207D0/en
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of CN108697746A publication Critical patent/CN108697746A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201680076032.7A 2015-12-17 2016-12-19 编码抗tcr复合体抗体或片段的病毒 Pending CN108697746A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1522334.0 2015-12-17
GBGB1522334.0A GB201522334D0 (en) 2015-12-17 2015-12-17 Method
GB1607463.5 2016-04-29
GBGB1607463.5A GB201607463D0 (en) 2016-04-29 2016-04-29 Method
GBGB1617206.6A GB201617206D0 (en) 2016-10-10 2016-10-10 Method
GB1617207.4 2016-10-10
GBGB1617207.4A GB201617207D0 (en) 2016-10-10 2016-10-10 Method
GB1617206.6 2016-10-10
PCT/EP2016/081818 WO2017103291A1 (en) 2015-12-17 2016-12-19 Virus encoding an anti-tcr-complex antibody or fragment

Publications (1)

Publication Number Publication Date
CN108697746A true CN108697746A (zh) 2018-10-23

Family

ID=57794239

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680074772.7A Pending CN108697745A (zh) 2015-12-17 2016-12-19 编码抗tcr复合体抗体或片段的b组腺病毒
CN201680076032.7A Pending CN108697746A (zh) 2015-12-17 2016-12-19 编码抗tcr复合体抗体或片段的病毒

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201680074772.7A Pending CN108697745A (zh) 2015-12-17 2016-12-19 编码抗tcr复合体抗体或片段的b组腺病毒

Country Status (19)

Country Link
US (3) US11970536B2 (enExample)
EP (2) EP3389683B8 (enExample)
JP (2) JP2019508017A (enExample)
KR (2) KR20180108590A (enExample)
CN (2) CN108697745A (enExample)
AU (2) AU2016372576A1 (enExample)
BR (2) BR112018012180A2 (enExample)
CA (1) CA3006859A1 (enExample)
CL (1) CL2018001611A1 (enExample)
CO (1) CO2018005945A2 (enExample)
DK (1) DK3389682T3 (enExample)
EA (2) EA201891022A1 (enExample)
IL (2) IL260027B (enExample)
MX (1) MX2018007249A (enExample)
MY (1) MY193281A (enExample)
PH (1) PH12018501291A1 (enExample)
SG (2) SG11201805136TA (enExample)
WO (2) WO2017103290A1 (enExample)
ZA (1) ZA201803523B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110551222A (zh) * 2019-08-27 2019-12-10 重庆市畜牧科学院 一种新型双功能抗体及其用途
CN112300991A (zh) * 2019-07-29 2021-02-02 赛雅思株式会社 抗原特异性t细胞的制造方法
WO2021073624A1 (zh) * 2019-10-17 2021-04-22 北京门罗生物科技有限公司 用于免疫治疗的嵌合抗原受体、制备方法及其应用
CN113355296A (zh) * 2021-06-07 2021-09-07 中国人民解放军空军军医大学 一种表达人ccl19的重组溶瘤新城疫病毒及其应用
CN114729031A (zh) * 2019-09-13 2022-07-08 艾德梅尔治疗协会 抗溶瘤病毒抗原抗体及其使用方法
CN114891126A (zh) * 2022-06-23 2022-08-12 上海安库生医生物科技有限公司 一种靶向fshr和cd3分子的双结合蛋白及其应用
CN115443332A (zh) * 2020-03-04 2022-12-06 生物日食治疗公司 制备活化免疫细胞的方法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3021859T (lt) 2013-10-25 2018-06-11 Psioxus Therapeutics Limited Onkolitiniai adenovirusai su heterologiniais genais
EP3261669B1 (en) 2015-02-25 2022-08-03 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
BR112018008865A8 (pt) 2015-11-02 2019-02-26 Five Prime Therapeutics Inc polipeptídeos do domínio extracelular cd80 e seu uso no tratamento do câncer
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
WO2017147553A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
CA3029426A1 (en) * 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
GB201713765D0 (en) * 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR102427563B1 (ko) 2016-08-29 2022-08-03 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
MX2019012849A (es) 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
KR20200136972A (ko) * 2018-03-30 2020-12-08 도모키 도도 종창 발생 억제형 종양 용해성 바이러스
EP3866924A4 (en) * 2018-06-29 2022-07-06 Krystal Biotech, Inc. COMPOSITIONS AND METHODS OF ANTIBODY DELIVERY
WO2020050630A1 (ko) 2018-09-07 2020-03-12 주식회사 케이티 비면허 대역에서 무선 통신을 수행하는 방법 및 장치
AU2019339535B2 (en) 2018-09-15 2025-11-20 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
WO2020143221A1 (zh) * 2019-01-07 2020-07-16 四川安可康生物医药有限公司 增强系统免疫应答的免疫溶瘤病毒组合药物及其应用
US20200215133A1 (en) * 2019-01-07 2020-07-09 Sichuan Oncocare Biopharmaceutical, Inc. Combination of immuno-oncolytic virus drugs for enhancing systemic immune response and application thereof
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
CN112063588A (zh) * 2020-08-13 2020-12-11 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN116249559A (zh) * 2020-08-31 2023-06-09 埃克苏马生物技术公司 抗独特型组合物及其使用方法
KR20220105139A (ko) * 2021-01-19 2022-07-26 광주과학기술원 Igsf4의 막 관통 도메인을 발현하는 t 세포 및 이의 이용
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
EP4332218A4 (en) * 2021-06-03 2024-09-18 Shanghai Yunying Biopharmaceutical Technology Co., Ltd. ONCOLYTIC VIRUS VECTOR AND USE THEREOF
CN116024175A (zh) * 2021-10-27 2023-04-28 南京北恒生物科技有限公司 工程化免疫细胞及其用途
AU2022418344A1 (en) 2021-12-23 2024-08-01 Helsingin Yliopisto Method for screening a signal peptide for efficient expression and secretion of a heterologous polypeptide in mammalian cells
WO2024243578A1 (en) 2023-05-25 2024-11-28 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015059303A1 (en) * 2013-10-25 2015-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
WO2015097220A1 (en) * 2013-12-23 2015-07-02 Psioxus Therapeutics Limited A method of making adenovirus and corresponding plasmids
WO2015155370A1 (en) * 2014-04-12 2015-10-15 Psioxus Therapeutics Limited Group b adenovirus modified in the e4orf4 region
WO2016174200A1 (en) * 2015-04-30 2016-11-03 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170269A3 (en) 1984-08-02 1987-09-23 Kao Corporation Medicated cosmetic compositions
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FI951138L (fi) 1993-07-13 1995-04-13 Rhone Poulenc Rorer Sa Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
DE19648650C2 (de) 1996-01-29 1998-07-02 Schering Ag Puffersysteme und deren Verwendung zur Stabilisierung pharmazeutischer Zubereitung
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
US6420524B1 (en) 1997-02-20 2002-07-16 Johns Hopkins University School Of Medicine Gain of function mutations in ATP-dependent transposition proteins
IL135507A0 (en) 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
CA2678259C (en) 1998-12-09 2016-10-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
ATE332364T1 (de) 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
CA2364562A1 (fr) 1999-04-09 2000-10-19 Aventis Pharma S.A. Composition destinee a la conservation d'adenovirus recombinants infectieux
DK1681353T3 (da) 1999-05-17 2010-01-04 Crucell Holland Bv Af adenovirus afledte genoverförselsvehikler indeholdende mindste ét element af adenovirus type 35
WO2000073478A2 (en) 1999-06-01 2000-12-07 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
WO2001011034A2 (en) 1999-08-09 2001-02-15 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
US7223593B2 (en) 2000-01-21 2007-05-29 Biovex Limited Herpes virus strains for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP2003534806A (ja) 2000-05-31 2003-11-25 ジェンベク、インコーポレイティッド アデノウイルスベクターのターゲティングの方法および組成物
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
WO2001094413A2 (en) 2000-06-06 2001-12-13 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
CA2474777A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
WO2003092594A2 (en) 2002-04-30 2003-11-13 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CN1934253A (zh) 2003-07-18 2007-03-21 昂尼克斯药物公司 用于治疗疾病的b亚组腺病毒载体
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
CA2567094C (en) 2004-05-26 2014-11-25 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CA2589602A1 (en) 2004-09-01 2006-04-13 Genvec, Inc. Adenoviral vectors able to transduce apcs, potential use in immune response generation
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
CA2620495A1 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
CN1961961B (zh) 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
JP2008050051A (ja) 2006-08-28 2008-03-06 Bokuson Uesuto:Kk ディスペンスヘッド
US8216819B2 (en) 2006-12-22 2012-07-10 Psioxus Therapeutics Limited Generation of oncolytic adenoviruses and uses thereof
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
CA2723580A1 (en) 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
AU2009299791B2 (en) 2008-10-01 2016-02-25 Amgen Research (Munich) Gmbh Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
WO2011043719A1 (en) 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
KR101957616B1 (ko) 2010-08-16 2019-03-12 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 아데노바이러스 조립 방법
WO2012038606A1 (en) 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
PE20141521A1 (es) 2011-08-23 2014-10-25 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
WO2013074507A2 (en) 2011-11-14 2013-05-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
GB201318793D0 (en) * 2013-10-24 2013-12-11 Plaquetec Ltd Vascular Biomarkers
CN106029889A (zh) 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
JP2017529070A (ja) 2014-08-27 2017-10-05 サイオクサス セラピューティクス リミテッド アデノウイルスの製造方法
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
KR102626276B1 (ko) 2015-03-17 2024-01-17 틸트 바이오세러퓨틱스 오이 이-특이적인 항체를 암호화하는 종양붕괴성 아데노바이러스 및 이와 관련된 방법 및 용도
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
KR20180118198A (ko) 2016-03-18 2018-10-30 난트셀, 인크. 수지상 세포 감염을 위한 멀티모달 벡터(multimodal vector for dendritic cell infection)
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR102427563B1 (ko) 2016-08-29 2022-08-03 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015059303A1 (en) * 2013-10-25 2015-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses armed with heterologous genes
WO2015097220A1 (en) * 2013-12-23 2015-07-02 Psioxus Therapeutics Limited A method of making adenovirus and corresponding plasmids
WO2015155370A1 (en) * 2014-04-12 2015-10-15 Psioxus Therapeutics Limited Group b adenovirus modified in the e4orf4 region
WO2016174200A1 (en) * 2015-04-30 2016-11-03 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
STEPHANE PAUL,ET AL: ""The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer"", 《CANCER IMMUNOL IMMUNOTHER》 *
STEPHANE PAUL,ET AL: ""Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies"", 《CANCER GENE THER》 *
胡泽斌 等: ""重组溶瘤腺病毒Ad-CD80-TPE-GM对Hep2细胞移植瘤的杀伤效应"", 《中国医药生物技术》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112300991A (zh) * 2019-07-29 2021-02-02 赛雅思株式会社 抗原特异性t细胞的制造方法
CN110551222A (zh) * 2019-08-27 2019-12-10 重庆市畜牧科学院 一种新型双功能抗体及其用途
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
CN114729031A (zh) * 2019-09-13 2022-07-08 艾德梅尔治疗协会 抗溶瘤病毒抗原抗体及其使用方法
CN114729031B (zh) * 2019-09-13 2024-07-02 艾德梅尔治疗协会 抗溶瘤病毒抗原抗体及其使用方法
WO2021073624A1 (zh) * 2019-10-17 2021-04-22 北京门罗生物科技有限公司 用于免疫治疗的嵌合抗原受体、制备方法及其应用
CN115443332A (zh) * 2020-03-04 2022-12-06 生物日食治疗公司 制备活化免疫细胞的方法
CN113355296A (zh) * 2021-06-07 2021-09-07 中国人民解放军空军军医大学 一种表达人ccl19的重组溶瘤新城疫病毒及其应用
CN114891126A (zh) * 2022-06-23 2022-08-12 上海安库生医生物科技有限公司 一种靶向fshr和cd3分子的双结合蛋白及其应用
CN114891126B (zh) * 2022-06-23 2023-05-09 上海安库生医生物科技有限公司 一种靶向fshr和cd3分子的双结合蛋白及其应用

Also Published As

Publication number Publication date
BR112018012179A2 (pt) 2018-12-04
JP2019508017A (ja) 2019-03-28
AU2016372576A1 (en) 2018-06-21
US11970536B2 (en) 2024-04-30
JP7064437B2 (ja) 2022-05-10
US20180369304A1 (en) 2018-12-27
IL260033A (en) 2018-07-31
EP3389682B1 (en) 2021-11-17
PH12018501291A1 (en) 2019-02-18
DK3389682T3 (da) 2022-01-24
EA201891021A1 (ru) 2018-11-30
KR102857666B1 (ko) 2025-09-10
MY193281A (en) 2022-09-30
WO2017103290A1 (en) 2017-06-22
CL2018001611A1 (es) 2018-09-14
IL260027B (en) 2022-07-01
US11155622B2 (en) 2021-10-26
KR20180107105A (ko) 2018-10-01
BR112018012180A2 (pt) 2018-12-04
US20190077865A1 (en) 2019-03-14
US20240247061A1 (en) 2024-07-25
MX2018007249A (es) 2019-05-16
EA201891022A1 (ru) 2019-01-31
CO2018005945A2 (es) 2018-08-21
KR20180108590A (ko) 2018-10-04
IL260027A (en) 2018-07-31
ZA201803523B (en) 2022-07-27
EP3389683B1 (en) 2023-03-29
EP3389683A1 (en) 2018-10-24
CA3006859A1 (en) 2017-06-22
AU2016369485B2 (en) 2024-02-01
JP2019502379A (ja) 2019-01-31
SG11201805137XA (en) 2018-07-30
EP3389682A1 (en) 2018-10-24
CN108697745A (zh) 2018-10-23
WO2017103291A1 (en) 2017-06-22
SG11201805136TA (en) 2018-07-30
EP3389683B8 (en) 2023-05-03
AU2016369485A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
CN108697746A (zh) 编码抗tcr复合体抗体或片段的病毒
AU2019279084B2 (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
KR102491752B1 (ko) 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
CN110785180B (zh) 溶瘤病毒疗法和免疫疗法
CN110856724B (zh) 包含核酸及car修饰的免疫细胞的治疗剂及其应用
KR102386029B1 (ko) 게놈 편집 면역 효과기 세포
CN107690479B (zh) 编码b7蛋白质的溶瘤腺病毒
KR20200032174A (ko) 강화된 키메라 항원 수용체 및 이의 용도
US20200392534A1 (en) Methods and Compositions Useful In Generating Non Canonical CD8+ T Cell Responses
KR20220009980A (ko) 조절된 합성 유전자 발현 시스템
CN114457044A (zh) 武装有异源基因的溶瘤腺病毒
KR20100113112A (ko) 개선된 포유동물 발현 벡터 및 이의 용도
CN115323000B (zh) 使用细胞分裂基因座控制细胞增殖的工具和方法
KR20160102024A (ko) 아데노바이러스 및 상응하는 플라스미드의 제조 방법
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
KR20220041214A (ko) Il-1 수퍼패밀리의 사이토카인의 시공적 제한 활성으로 무장된 면역반응성 세포
CN106687592B (zh) 一种重组质粒、其构建的重组疟原虫及其应用
CN106086076A (zh) 一种具有炎症基础的肺癌动物模型的建立方法
HK40082332A (zh) 使用细胞分裂基因座控制细胞增殖的工具和方法
Verna et al. induction of antihuman c–c chemokine receptor Type 5 antibodies by a Bovine herpesvirus Type-4 Based Vector
HK40024932A (en) Therapeutic agent comprising nucleic acid and car-modified immune cell and application thereof
HK40024932B (en) Therapeutic agent comprising nucleic acid and car-modified immune cell and application thereof
HK40049493B (zh) 包含核酸及car修饰的免疫细胞的治疗剂及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181023